Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Health-Related Quality-of-Life Assessment of Obinutuzumab plus Bendamustine versus Bendamustine in Patients with Rituximab-Refractory Indolent NHL: Results of the GADOLIN Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Effect of Ibrutinib versus Temsirolimus Treatment on Lymphoma Symptoms in Patients with Previously Treated Mantle-Cell Lymphoma (MCL): Results of the RAY (MCL3001) Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma